Eroxon Intense Home User Test Reports Stronger ED Gel Results

A stronger version of a drug-free erectile dysfunction gel has passed another real-world test. The Eroxon Intense Home User Test, announced this week by consumer healthcare company Futura Medical, found that men using the optimised gel were satisfied with the hardness of their erections in 82 percent of sexual encounters. The study followed 115 men aged 18 to 59, most of them living with mild to moderate erectile dysfunction, according to the company announcement. The updated presentation is built to dispense and apply more consistently in everyday use, and the company said it beat both the original Intense formula and the current Eroxon gel on every key measure. Futura Medical intends to commercialise the new formula in the first half of next year.

The comparison is unusually clean for this kind of consumer research. The new test used a study design broadly identical to a home user test the company ran earlier, so results could be stacked against the previous round without the usual mismatch of methods. It is exactly the baseline the Eroxon Intense Home User Test was designed to beat. In that earlier round, participants reported hardness satisfaction in 71 percent of encounters with the original Intense presentation and 70 percent with the standard Eroxon gel, according to the company. The optimised presentation improved on both, the company said in a statement, and men also reported that erections lasted long enough for intercourse in 87 percent of encounters, against 85 percent and 84 percent for the original Intense and the standard gel in the previous test.

Clinically meaningful gains on the IIEF scale

Satisfaction scores only tell part of the story. The trial also tracked erectile function on the IIEF-EF scale, the standard clinical questionnaire that urologists use to grade severity. Participants on the optimised Intense presentation recorded an average improvement of 7.86 points from baseline, compared with a 4.82-point gain for the original Intense presentation. That clears the threshold clinicians generally treat as a meaningful change, which suggests the difference is medically relevant, not just noticeable. The effect was strongest in men with moderate erectile dysfunction. In the earlier test, 73 percent of that group achieved a clinically meaningful gain, and the optimised presentation pushed that share higher still, according to TickStock's coverage of the results.

How the gel works and when it could reach shelves

Eroxon takes a different route from the prescription pills that dominate the category. It is a topical gel applied before intercourse, and its formula combines volatile components that create a cooling sensation followed by a warming one. That sequence stimulates nerve sensors in the glans, prompting smooth muscle relaxation, tumescence and erection, according to Futura Medical's product information. The efficacy of the base gel was demonstrated in two Phase 3 trials involving 300 men with mild, moderate and severe erectile dysfunction, which measured improvement against baseline. The Intense variant adds a faster-acting, higher-sensation formula, and regulatory clearance reported earlier this year covers launch across the European Economic Area and the United Kingdom under the company's existing CE and UKCA certifications. Commercial partner Cooper Consumer Health is set to bring the product to market in its licensed territories.

Ken James, Futura's executive director and head of research and development, said the company is encouraged by the additional test, adding that clear positioning and communication around how to use the product will be critical to customer satisfaction. The trial itself backs that point: the optimised presentation changed nothing about the active formula, yet satisfaction scores rose, which suggests that ease of use matters as much as chemistry. For younger men especially, who make up a growing share of the ED market and often avoid the doctor's office, a gel that works without a prescription could lower the bar for getting help. The launch window early next year gives the company months to fine-tune that messaging. It also lands amid a busy stretch for sexual health research, from the STI morning-after pill's promise and limits to new data on how common medications can erode sexual function.

There are caveats, and they deserve a plain hearing. A home user test is not a clinical trial. Participants knew what they were using, and there was no placebo arm, so some of the satisfaction scores reflect expectation as much as effect. Futura Medical frames the test as real-world validation of its earlier clinical programme, not a replacement for it. Even so, the pattern is consistent: each round of testing has come back stronger than the last, and the optimised presentation now sits ahead of the original gel on every published measure. If the launch lands on schedule, the question becomes whether that performance holds up outside a study, where reviews are written in bedrooms rather than questionnaires. More on the announcement is available in the company announcement and in TickStock's report.